245 related articles for article (PubMed ID: 31631745)
1. Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.
Hoffman RM; Lobo T; Van Den Eeden SK; Davis KM; Luta G; Leimpeter AD; Aaronson D; Penson DF; Taylor K
Med Decis Making; 2019 Nov; 39(8):962-974. PubMed ID: 31631745
[No Abstract] [Full Text] [Related]
2. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.
Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM
BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791
[TBL] [Abstract][Full Text] [Related]
3. Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
Taylor KL; Hoffman RM; Davis KM; Luta G; Leimpeter A; Lobo T; Kelly SP; Shan J; Aaronson D; Tomko CA; Starosta AJ; Hagerman CJ; Van Den Eeden SK
Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1240-50. PubMed ID: 27257092
[TBL] [Abstract][Full Text] [Related]
4. Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.
Kelly SP; Van Den Eeden SK; Hoffman RM; Aaronson DS; Lobo T; Luta G; Leimpter AD; Shan J; Potosky AL; Taylor KL
J Urol; 2016 Sep; 196(3):734-40. PubMed ID: 27091570
[TBL] [Abstract][Full Text] [Related]
5. Choosing active surveillance versus curative treatment in a population-based survey of men with low-risk prostate cancer.
Xu J; Janisse J; Goodman M
Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 36696653
[TBL] [Abstract][Full Text] [Related]
6. Decision-making processes among men with low-risk prostate cancer: A survey study.
Hoffman RM; Van Den Eeden SK; Davis KM; Lobo T; Luta G; Shan J; Aaronson D; Penson DF; Leimpeter AD; Taylor KL
Psychooncology; 2018 Jan; 27(1):325-332. PubMed ID: 28612468
[TBL] [Abstract][Full Text] [Related]
7. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
8. The effect of urologist experience on choosing active surveillance for prostate cancer.
Chu WG; Kim BJ; Slezak J; Harrison TN; Gelfond J; Jacobsen SJ; Chien GW
World J Urol; 2015 Nov; 33(11):1701-6. PubMed ID: 25761737
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
10. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
11. Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
Xu J; Bock CH; Janisse J; Woo J; Cher ML; Ginsburg K; Yacoub R; Goodman M
Cancer; 2024 May; 130(10):1797-1806. PubMed ID: 38247317
[TBL] [Abstract][Full Text] [Related]
12. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal regret after treatment for low- and intermediate-risk prostate cancer.
Hurwitz LM; Cullen J; Kim DJ; Elsamanoudi S; Hudak J; Colston M; Travis J; Kuo HC; Rice KR; Porter CR; Rosner IL
Cancer; 2017 Nov; 123(21):4252-4258. PubMed ID: 28678408
[TBL] [Abstract][Full Text] [Related]
14. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
15. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Stewart ST; Bhatnagar V; Sweeney CJ; Stahl JE; McMahon PM
JAMA; 2010 Dec; 304(21):2373-80. PubMed ID: 21119084
[TBL] [Abstract][Full Text] [Related]
17. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
20. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.
Myers RE; Leader AE; Censits JH; Trabulsi EJ; Keith SW; Petrich AM; Quinn AM; Den RB; Hurwitz MD; Lallas CD; Hegarty SE; Dicker AP; Zeigler-Johnson CM; Giri VN; Ayaz H; Gomella LG
J Cancer Educ; 2018 Feb; 33(1):180-185. PubMed ID: 27418065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
